CORNELY, O.A., S. ARIKAN- AKDAGLI, E. DANNAOUI, A.H. GROLL, K. LAGROU, A. CHAKRABARTI, F. LANTERNIER, L. PAGANO, A. SKIADA, M. AKOVA, M.C. ARENDRUP, T. BOEKHOUT, A. CHOWDHARY, M. CUENCA- ESTRELLA, Tomáš FREIBERGER, J. GUINEA, J. GUARRO, S. DE HOOG, W. HOPE, E. JOHNSON, S. KATHURIA, M. LACKNER, C. LASS- FLÖRL, O. LORTHOLARY, J.F. MEIS, J. MELATIADIS, P. MUNOZ, M. RICHARDSON, E. ROILIDES, A.M. TORTORANO, A.J. ULLMANN, A. VAN DIEPENINGEN, P. VERWEIJ and G. PETRIKKOS. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clinical Microbiology and Infection. Hoboken (USA): Wiley- Blackwell, 2014, vol. 20, April, p. 5-26. ISSN 1198-743X. doi:10.1111/1469-0691.12371.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013
Authors CORNELY, O.A. (276 Germany), S. ARIKAN- AKDAGLI (792 Turkey), E. DANNAOUI (250 France), A.H. GROLL (276 Germany), K. LAGROU (56 Belgium), A. CHAKRABARTI (356 India), F. LANTERNIER (250 France), L. PAGANO (380 Italy), A. SKIADA (300 Greece), M. AKOVA (792 Turkey), M.C. ARENDRUP (208 Denmark), T. BOEKHOUT (528 Netherlands), A. CHOWDHARY (356 India), M. CUENCA- ESTRELLA (724 Spain), Tomáš FREIBERGER (203 Czech Republic, guarantor, belonging to the institution), J. GUINEA (724 Spain), J. GUARRO (724 Spain), S. DE HOOG (528 Netherlands), W. HOPE (826 United Kingdom of Great Britain and Northern Ireland), E. JOHNSON (826 United Kingdom of Great Britain and Northern Ireland), S. KATHURIA (356 India), M. LACKNER (40 Austria), C. LASS- FLÖRL (40 Austria), O. LORTHOLARY (250 France), J.F. MEIS (528 Netherlands), J. MELATIADIS (300 Greece), P. MUNOZ (724 Spain), M. RICHARDSON (826 United Kingdom of Great Britain and Northern Ireland), E. ROILIDES (300 Greece), A.M. TORTORANO (380 Italy), A.J. ULLMANN (276 Germany), A. VAN DIEPENINGEN (528 Netherlands), P. VERWEIJ (528 Netherlands) and G. PETRIKKOS (300 Greece).
Edition Clinical Microbiology and Infection, Hoboken (USA), Wiley- Blackwell, 2014, 1198-743X.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 10600 1.6 Biological sciences
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 5.768
RIV identification code RIV/00216224:14740/14:00076471
Organization unit Central European Institute of Technology
Doi http://dx.doi.org/10.1111/1469-0691.12371
UT WoS 000332445700002
Keywords in English LIPOSOMAL AMPHOTERICIN-B; INVASIVE FUNGAL-INFECTIONS; ORBITAL-CEREBRAL MUCORMYCOSIS; IN-VITRO SUSCEPTIBILITIES; FRAGMENT LENGTH POLYMORPHISM; HEMATOLOGY-ONCOLOGY PATIENTS; ORGAN TRANSPLANT RECIPIENTS; DESORPTION IONIZATION-TIME;
Tags kontrola MP, MP, rivok
Tags International impact, Reviewed
Changed by Changed by: Martina Prášilová, učo 342282. Changed: 17. 4. 2015 11:24.
Abstract
These European Society for Clinical Microbiology and Infectious Diseases and European Confederation of Medical Mycology Joint Clinical Guidelines focus on the diagnosis and management of mucormycosis. Only a few of the numerous recommendations can be summarized here. To diagnose mucormycosis, direct microscopy preferably using optical brighteners, histopathology and culture are strongly recommended. Pathogen identification to species level by molecular methods and susceptibility testing are strongly recommended to establish epidemiological knowledge. The recommendation for guiding treatment based on MICs is supported only marginally. Imaging is strongly recommended to determine the extent of disease. To differentiate mucormycosis from aspergillosis in haematological malignancy and stem cell transplantation recipients, identification of the reverse halo sign on computed tomography is advised with moderate strength. For adults and children we strongly recommend surgical debridement in addition to immediate first-line antifungal treatment with liposomal or lipid-complex amphotericin B with a minimum dose of 5mg/kg/day. Amphotericin B deoxycholate is better avoided because of severe adverse effects. For salvage treatment we strongly recommend posaconazole 4x200mg/day. Reversal of predisposing conditions is strongly recommended, i.e. using granulocyte colony-stimulating factor in haematological patients with ongoing neutropenia, controlling hyperglycaemia and ketoacidosis in diabetic patients, and limiting glucocorticosteroids to the minimum dose required. We recommend against using deferasirox in haematological patients outside clinical trials, and marginally support a recommendation for deferasirox in diabetic patients. Hyperbaric oxygen is supported with marginal strength only. Finally, we strongly recommend continuing treatment until complete response demonstrated on imaging and permanent reversal of predisposing factors.
PrintDisplayed: 12. 8. 2022 17:23